BKYIBKYITechnology · Security & Protection Services

BKYI Stock Forecast: BIO-key International, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.98
−5.71% on the day

The median 12-month analyst price target for BIO-key International, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$4.3M
Ticker Nerd rank
55/ 100
Median analyst target
$20
Analysts covering
1
Revenue$1.9M+13.1% y/y
Operating income−$529K
Net income−$577K
Free cash flow−$846K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
−13.9%
YTD
−63.3%
1Y
−78.5%
From 52W high
−78.5%
From 52W low
+20.0%
$1.65
$9.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores BIO-key International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
55/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Volatility
62
Growth
60
Quality
59
Issuance
52
Momentum
39
Value
24
Revisions
20

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (20): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BKYI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BKYI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26BKYIHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$20
Low
$20
Median
$20
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Mar 2021Maxim GroupUpgradeBuy$6.00
25 Nov 2020Maxim GroupDowngradeHold—
4 Oct 2019Maxim GroupDowngradeHold—
16 Aug 2018Maxim GroupMaintainsBuy$5.50 → $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BKYI.

Market Radar

This page is one stock. Monday covers all of them.

BKYI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BKYI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, BIO-key International, Inc. returned −78.5% against +6.9% for the S&P 500, dividends included.

BKYI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26BKYIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BKYI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.6×

Cheaper than 75% of US stocks

Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
87.2%

Higher than 95% of US stocks

Operating margin
−48.5%

Higher than 18% of US stocks

Net margin
−89.8%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−94.7%

Higher than 14% of US stocks

Return on assets
−21.2%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BIO-key International, Inc. has a market value of $4.3M and an enterprise value of $2.2M.

  • Revenue in the twelve months to 30 June 2026: $6.7M. The latest quarter grew 13.1% year on year.

  • Net income over the same four quarters: −$6.0M, a −90.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.11.

  • Free cash flow in the twelve months to 30 June 2026: −$4.2M, after $6K of capital spending.

  • Shares outstanding: 1.1M.

  • forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BIO-key International, Inc. employs 41 people — $163K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BKYI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSecurity & Protection Services
CompanyMarket capTKN rank
BKYIBIO-key International, Inc.$4.3M55
GFAIGuardforce AI Co., Ltd.$2.6M12
SUGPSU Group Holdings Ltd.$2.5M5
IVDAIveda Solutions, Inc.$2.3M7
KSCPKnightscope, Inc.$10.7M31
BAERBridger Aerospace Group Holdings, Inc.$16.8M11
SNTSenstar Technologies Corp.$40.1M13

Take a look at BKYI’s peer groups, ranked by the model: tech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own BIO-key International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BKYI

What is the BKYI stock price forecast for 2026-2027?

The median 12-month analyst price target for BIO-key International, Inc. is $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BKYI stock a buy right now?

Of the 1 analyst covering BIO-key International, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BIO-key International, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BKYI?

As at 21 Nov 2026, BIO-key International, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will BKYI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $20, and Ticker Nerd's factor model ranks BIO-key International, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BKYI stock forecast for 2030?

No analyst covering BIO-key International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BKYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has BKYI stock performed over the past year?

BIO-key International, Inc. returned -78.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BIO-key International, Inc. do?

BIO-key International, Inc. is a biometrics and identity access management company that develops fingerprint authentication and secure access software for organizations. BIO-key International, Inc. offers cloud-based and on-premise identity platforms, including PortalGuard and PortalGuard IDaaS, to support multi-factor authentication, single sign-on, passwordless login, privilege access control, and user provisioning.

Company

About BIO-key International, Inc.

BIO-key International, Inc. is a biometrics and identity access management company that develops fingerprint authentication and secure access software for organizations. BIO-key International, Inc. offers cloud-based and on-premise identity platforms, including PortalGuard and PortalGuard IDaaS, to support multi-factor authentication, single sign-on, passwordless login, privilege access control, and user provisioning. Its product portfolio also includes biometric identity verification tools, civil and large-scale identification systems, mobile authentication applications, and fingerprint readers for enterprise use. The company serves commercial, government, and education customers across industries that require secure workforce, student, citizen, and customer access management. Headquartered in Holmdel, New Jersey, and founded in 1993, BIO-key International, Inc. focuses on combining biometric hardware and software to simplify digital identity security and reduce reliance on traditional credentials.

CEO Mr. Michael W. DePasquale · 41 employees · United States · https://www.bio-key.com